These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 14626000)
1. Setting prices for new vaccines (in advance). McGuire TG Int J Health Care Finance Econ; 2003 Sep; 3(3):207-24. PubMed ID: 14626000 [TBL] [Abstract][Full Text] [Related]
2. Pharmaceutical companies' variation of drug prices within and among countries can improve long-term social well-being. Lichtenberg FR Health Aff (Millwood); 2011 Aug; 30(8):1539-44. PubMed ID: 21821571 [TBL] [Abstract][Full Text] [Related]
3. Differential pricing for pharmaceuticals: reconciling access, R&D and patents. Danzon PM; Towse A Int J Health Care Finance Econ; 2003 Sep; 3(3):183-205. PubMed ID: 14625999 [TBL] [Abstract][Full Text] [Related]
4. Price regulation of pharmaceuticals in Canada. Anis AH; Wen Q J Health Econ; 1998 Jan; 17(1):21-38. PubMed ID: 10176313 [TBL] [Abstract][Full Text] [Related]
5. The GO License: only part of the solution. Batson A; Milstien JB Health Aff (Millwood); 2008; 27(1):140-2. PubMed ID: 18180489 [TBL] [Abstract][Full Text] [Related]
6. Vaccine supply, demand, and policy: a primer. Muzumdar JM; Cline RR J Am Pharm Assoc (2003); 2009; 49(4):e87-99. PubMed ID: 19589753 [TBL] [Abstract][Full Text] [Related]
7. Effects of the German reference drug program on ex-factory prices of prescription drugs: a panel data approach. Augurzky B; Göhlmann S; Gress S; Wasem J Health Econ; 2009 Apr; 18(4):421-36. PubMed ID: 18677725 [TBL] [Abstract][Full Text] [Related]
9. Price regulation in the pharmaceutical industry: prescription or placebo? Abbott TA J Health Econ; 1995 Dec; 14(5):551-65. PubMed ID: 10156501 [TBL] [Abstract][Full Text] [Related]
10. Price differentiation and transparency in the global pharmaceutical marketplace. Ridley DB Pharmacoeconomics; 2005; 23(7):651-8. PubMed ID: 15987224 [TBL] [Abstract][Full Text] [Related]
11. Incentives and disincentives to drug innovation: evidence from recent literature. Lee Mendoza R J Med Econ; 2019 Aug; 22(8):713-721. PubMed ID: 31038374 [No Abstract] [Full Text] [Related]
12. Addressing supply side barriers to introduction of new vaccines to the developing world. McElligott S Am J Law Med; 2009; 35(2-3):415-41. PubMed ID: 19697757 [TBL] [Abstract][Full Text] [Related]
13. Perspective of vaccine manufacturers on financing pediatric and adolescent vaccines in the United States. Shen AK; Rodewald LE; Birkhead GS Pediatrics; 2009 Dec; 124 Suppl 5():S540-7. PubMed ID: 19948586 [TBL] [Abstract][Full Text] [Related]
14. Do generics offer significant savings to the UK National Health Service? Kanavos P Curr Med Res Opin; 2007 Jan; 23(1):105-16. PubMed ID: 17257472 [TBL] [Abstract][Full Text] [Related]
15. Should the US allow prescription drug reimports from Canada? Pecorino P J Health Econ; 2002 Jul; 21(4):699-708. PubMed ID: 12146598 [TBL] [Abstract][Full Text] [Related]
16. Trends in childhood vaccine purchase costs in the US public sector: 1996-2014. Chen W; Messonnier M; Zhou F Vaccine; 2016 Sep; 34(39):4706-4711. PubMed ID: 27522176 [TBL] [Abstract][Full Text] [Related]
17. Market-based licensing for HPV vaccines in developing countries. Outterson K; Kesselheim AS Health Aff (Millwood); 2008; 27(1):130-9. PubMed ID: 18180488 [TBL] [Abstract][Full Text] [Related]
18. No Shot: US Vaccine Prices And Shortages. Ridley DB; Bei X; Liebman EB Health Aff (Millwood); 2016 Feb; 35(2):235-41. PubMed ID: 26858375 [TBL] [Abstract][Full Text] [Related]
19. Cost of production of live attenuated dengue vaccines: a case study of the Instituto Butantan, Sao Paulo, Brazil. Mahoney RT; Francis DP; Frazatti-Gallina NM; Precioso AR; Raw I; Watler P; Whitehead P; Whitehead SS Vaccine; 2012 Jul; 30(32):4892-6. PubMed ID: 22406455 [TBL] [Abstract][Full Text] [Related]